Last updated on September 2014

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery


Brief description of study

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery.

Detailed Study Description

OBJECTIVES: Primary - To determine the safety of BLP25 liposome vaccine and bevacizumab after definitive chemoradiotherapy and consolidation chemotherapy in patients with newly diagnosed, unresectable stage IIIA or IIIB nonsquamous cell non-small cell lung cancer. Secondary - To evaluate the overall survival and progression-free in patients treated with this regimen. - To evaluate the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. - Chemoradiotherapy: Patients receive paclitaxel IV over 1 hour and carboplatin IV over 15-30 minutes once a week for 6 weeks. Patients also undergo concurrent definitive radiotherapy 5 days a week for 6½ weeks. Patients with complete response (CR), partial response (PR), or stable disease (SD) proceed to consolidation chemotherapy. - Consolidation chemotherapy: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR, PR, or SD proceed to maintenance therapy. - Maintenance therapy: Patients receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and BLP25 liposome vaccine. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and BLP25 liposome vaccine subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 5 years.

Clinical Study Identifier: NCT00828009

Contact Investigators or Research Sites near you

Start Over

Stanford Cancer Center

Stanford, CA United States
  Connect »

St. Joseph Medical Center

Bloomington, IL United States
  Connect »

Graham Hospital

Canton, IL United States
  Connect »

Memorial Hospital

Carthage, IL United States
  Connect »

Saint Joseph Hospital

Chicago, IL United States
  Connect »

Eureka Community Hospital

Eureka, IL United States
  Connect »

Galesburg Clinic, PC

Galesburg, IL United States
  Connect »

Mason District Hospital

Havana, IL United States
  Connect »

Kellogg Cancer Care Center

Highland Park, IL United States
  Connect »

Community Cancer Center

Normal, IL United States
  Connect »

Proctor Hospital

Peoria, IL United States
  Connect »

Perry Memorial Hospital

Princeton, IL United States
  Connect »

Elkhart General Hospital

Elkhart, IN United States
  Connect »

Howard Community Hospital

Kokomo, IN United States
  Connect »

Memorial Hospital of South Bend

South Bend, IN United States
  Connect »

McFarland Clinic, PC

Ames, IA United States
  Connect »

Borgess Medical Center

Kalamazoo, MI United States
  Connect »

Bronson Methodist Hospital

Kalamazoo, MI United States
  Connect »

West Michigan Cancer Center

Kalamazoo, MI United States
  Connect »

Lakeside Cancer Specialists, PLLC

Saint Joseph, MI United States
  Connect »

Immanuel Medical Center

Omaha, NE United States
  Connect »

Lakeside Hospital

Omaha, NE United States
  Connect »

Lewistown Hospital

Lewistown, PA United States
  Connect »

Mount Nittany Medical Center

State College, PA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.